ISSN: 0970-938X (Print) | 0976-1683 (Electronic)

Biomedical Research

An International Journal of Medical Sciences

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Abstract

Effect of different therapeutic regimens on the elderly patients with multiple myeloma

Objective: To explore the effect of different therapeutic regimens on the patients with Multiple Myeloma (MM).

Methods: In Melphalan and Prednisone (MP) group, patients received 8 mg/m2/d melphalan and 60 mg/m2/d prednisone for 6 cycles (7 days each cycle). In M2 (VMBCP) group, patients received 1 mg/m2/d vincristine, 20 mg/m2/d carmustine and 400 mg/m2/d cyclophosphamide on Day 1, 8 mg/m2/d melphalanon Day 1-4, and 30 mg/m2/d prednisone on Day 1-14 for 6 cycles (14 days each cycle). In M2 and MP group, two regimens were applied alternately for 6 cycles. In Multiple CCT groups, multiple combination chemotherapy were adopted, including VMCP regimen (0.4 mg/m2/d vincristine and 100 mg/m2/d cyclophosphamide on Day 1, 8 mg/m2/d melphalan on Day 1-4 and 60 mg/m2/d prednisone Day 1-14), VBAP regimen (1 mg/m2/d vincristine and 75-100 mg/m2/d carmustine on Day 1, 30 mg/m2/d doxorubicin and 60 mg/m2/d prednisone on Day 1-4), VAD regimen (0.4 mg/m2/d vincristine on Day 1-4 with infusion for 24 h, 40 mg/m2/d dexamethasone on Day 1-4, 9-12 and 1720), CVP regimen (100 mg/m2/d cyclophosphamide and 0.4 mg/m2/d vincristine on Day 1-4, 60 mg/m2/d prednisone on Day 1-14) and ECP regimen (100 mg/m2/d etoposide on Day 3-5, 100 mg/m2/d cyclophosphamide and 60 mg/m2/d prednisone on Day 1-5). Response rate and survival time of different groups are compared.

Results: The total response rate of 100 patients treated with conventional chemotherapy was 46.0%, and complete response rate and partial response rate were 15.0% and 31.0%, respectively. The total response rate of patients treated with combination chemotherapy was significantly higher than that of patients treated with melphalan and prednisone (59.1% vs. 29.2%, t=38.456, P<0.05). The median survival time, 3 and 5 year overall survival of 108 MM patients were 31.0 months, 33.0% and 16.1%, respectively.

Conclusions: Combination chemotherapy could be used for the patients with multiple myeloma.


Author(s): Chen Ge, Peng Cao, Xiang-yang Xu

Abstract | Full-Text | PDF

Share this  Facebook  Twitter  LinkedIn  Google+